Cancer Clinical Trials Results
Tissue and Body Fluid Analysis from Patients with Bladder Cancer and Other Urothelial Cancers of the Urinary Tract
||Main Campus|| || ||Bladder, Urethral
A Phase II Trial of Pembrolizumab (MK-3475) in Subjets with Advanced / Unresectable or Metastatic Urothelial Cancer.
||Main Campus|| ||Phase 2||Bladder
A Phase III, open-label, multicenter, randomized study of atezolizumab (anti-pd-l1 antibody) versus observation as adjuvant therapy in patients with pd-l1-selected, high-risk muscle-invasive bladder cancer after cystectomy
||Main Campus|| ||Phase 3||Bladder
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
||Fairview, Florida Weston, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster|| ||Phase 2||Bladder
Cancer Answers & Appointments
Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.
Monday through Friday from 8 a.m. – 4:30 p.m. (ET).
Resources for medical professionals
- Outpatient appointment referrals: 216.444.7923 or 866.223.8100
- Inpatient hospital transfers: 800.553.5056
- Referring Physician Concierge: 216.444.6196 or 216.312.4910.
Search available cancer clinical trials by disease, hospital, phase or number.
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2015 Cleveland Clinic. All rights reserved.